


# SEQUENCE LISTING



<110> PERLAN THERAPEUTICS  
FANG, FANG

<120> MULTIVALENT RECOMBINANT ANTIBODIES FOR TREATING HRV INFECTIONS

<130> 014357-0278749

<140> 09/555,446

<141> 2000-08-16

<150> PCT/US98/25422

<151> 1998-11-30

<150> US 60/067,119

<151> 1997-12-01

<150> US 60/083,046

<151> 1998-04-24

<150> US 60/090,632

<151> 1998-06-25

<160> 15

<170> PatentIn Ver. 3.1

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: human  
peptide residues

<400> 1

Gln Thr Ser Val Ser

1 5

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: human  
peptide residues

<400> 2

Ser Cys Asp Gln Pro Lys

1 5

<210> 3  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: human  
peptide residues

<400> 3  
Lys Glu Leu Leu Leu Pro Gly Asn Asn Arg  
1 5 10

<210> 4  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: human  
peptide residues

<400> 4  
Pro Asp Gly Gln Ser Thr Ala Lys  
1 5

<210> 5  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: linker sequence

<400> 5  
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser  
1 5 10 15

<210> 6  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: hinge region sequence

<400> 6  
Pro Gln Pro Gln Pro Lys Pro Gln Pro Gln Pro Gln Pro Lys  
1 5 10 15

Pro Gln Pro Lys Pro Glu Pro Glu  
20

<210> 7  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: human complementary  
peptide sequence

<400> 7  
Val Cys Arg His Arg  
1 5

<210> 8  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: human complementary  
peptide sequence

<400> 8  
Gly His Arg Cys Leu  
1 5

<210> 9  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: human complementary  
peptide sequence

<400> 9  
Leu Gly Leu Val Thr Gly  
1 5

<210> 10  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: human complementary  
peptide sequence

<400> 10  
Arg Thr Leu Val Gly Phe  
1 5

<210> 11  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: human complementary  
peptide sequence

<400> 11  
Pro Val Val Pro Arg Gln Glu Gln Leu Leu  
1 5 10

<210> 12  
<211> 10  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: human complementary  
peptide sequence

<400> 12  
Phe Leu Asn Glu Asp Gly Pro Leu Leu Ala  
1 5 10

<210> 13  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: human complementary  
peptide sequence

<400> 13  
Phe Ser Cys Ser Leu Pro Ile Arg  
1 5

<210> 14  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: human complementary  
peptide sequence

<400> 14  
Gly Ile Pro Val Ser Cys Arg Phe  
1 5

<210> 15

<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: primer sequence

<400> 15  
ccctcatagt taagcgtaac g

21